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Background: Dofetilide is FDA-approved for maintaining sinus rhythm in patients with persistent atrial fibrillation (AF); however, it is also frequently 
used in patients with paroxysmal AF.
Methods: We studied 135 AF patients initiated on dofetilide at our institution between October 2002 and July 2008 in order to compare the 
efficacy and outcomes in paroxysmal (n=69) vs. persistent AF (n=66).
Results: The average age was 60±11 years. The incidence of male gender, coronary disease, hypertension, diabetes, hyperlipidemia, left atrial 
size >4cm, and LVEF <40% did not differ significantly between the paroxysmal and persistent AF groups. Dofetilide was discontinued in 20 patients 
(15%) during the initiation admission and in 21 patients (16%) within 6 weeks of initiation (24 due to inefficacy, 9 with excessive QT prolongation, 
4 with Torsades de Pointes, 3 unable to afford the medication, and 1 with worsening renal function). At 12 months, 52% of paroxysmal and 55% of 
persistent AF patients were clinically free from AF (p=0.33, panel a). At 24 months, 64% of paroxysmal and 39% of persistent AF patients remained 
on dofetilide because of continued clinical benefit (p=0.003, panel b).
Conclusion: The majority of patients who discontinue dofetilide do so early in its use. While dofetilide is FDA approved for the treatment of 
persistent AF, it appears to have a comparable efficacy and safety profile in paroxysmal AF. Furthermore, dofetilide is more likely to be continued in 
paroxysmal AF patients longterm.
 
